NasdaqGM:APGEBiotechs
A Look At Apogee Therapeutics (APGE) Valuation As Great Point Partners Lifts Its Stake
Great Point Partners has increased its exposure to Apogee Therapeutics (APGE), with filings showing the fund now holds about 9.15% of its assets in the company, alongside advancing atopic dermatitis and asthma programs.
See our latest analysis for Apogee Therapeutics.
Apogee’s latest US$70.05 share price comes after a mixed few months, with a slightly negative 90 day share price return but a very strong 1 year total shareholder return of about 123%, as investors focus on upcoming trial...